GSK announces Nuvalent tender offer, shares supported by oncology push
26.06.2026 - 11:46:03 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-26, 11:45.
GSK plc (GB0009252882) has announced the commencement of a tender offer to acquire U.S. oncology specialist Nuvalent, Inc., adding another targeted cancer deal to its specialty medicines strategy as reported in recent company and market coverage.Company snapshot and deal overview
What the Nuvalent deal means
The Nuvalent tender offer continues GSK’s recent focus on oncology, following earlier signals that the new CEO is ready to pursue larger cancer ambitions, according to a June report by The Wall Street Journal.WSJ analysis on GSK’s cancer ambitions The planned acquisition is positioned to strengthen GSK’s pipeline in targeted therapies, adding clinical-stage assets focused on oncogenic drivers.
Nuvalent develops small-molecule kinase inhibitors that address resistance and selectivity challenges in cancer treatment, a segment that fits directly into GSK’s specialty medicines focus and its ambition to grow higher-margin innovative drugs.Yahoo Finance discussion of GSK’s anti-infectives and specialty focus The tender offer structure allows GSK to secure control of Nuvalent while preserving operational continuity during integration.
Analyst view and stock context
On the London Stock Exchange, GSK shares recently traded around 1,983.50 pence, with a 52-week range from roughly 1,288.61 to 2,282 pence and a market capitalization close to £78 billion, according to Hargreaves Lansdown.Hargreaves Lansdown price and market data This places the stock broadly mid-range versus its recent high and low marks.
Consensus analysis compiled by MarketBeat shows an average price target of about 2,034 pence for GSK, implying limited upside from current levels and an overall "Hold" stance among covering analysts, with targets between 1,500 and 2,500 pence.MarketBeat consensus and price target data The Nuvalent tender offer adds another data point to that debate, as investors weigh incremental oncology exposure against valuation and execution risk.
All news and data on the GSK shares
Further company announcements, analyst updates and price data on GSK are collected on the dedicated topic page and in the investor relations section.
How GSK makes its money
GSK’s core business centers on specialty medicines, vaccines and consumer health products, with 2025 revenue of about $43.1 billion generated largely from pharmaceutical and vaccine sales worldwide, per a company snapshot.Company profile with revenue data The group’s specialty medicines segment covers therapies in areas such as respiratory, HIV, oncology and immunology, where differentiated, high-value drugs can support margins and long-term growth.
Where the stock trades today
GSK shares (GB0009252882) trade on the London Stock Exchange, with recent prices around 1,983.50 pence and a market capitalization near £78.31 billion as of 2026-06-25, 12:20, according to Hargreaves Lansdown.Latest LSE trading data
Key data on the GSK shares
- Company: GSK plc
- ISIN: GB0009252882
- WKN: 940561
- Ticker: GSK
- Trading venue: London Stock Exchange
- Price (as of 2026-06-25, 12:20): 1,983.50 pence
- Market cap: £78.31 billion (as of 2026-06-25)
- Sector / industry: Pharmaceuticals & Biotechnology
- Index membership: FTSE 100
- Next earnings date: not officially scheduled
Disclaimer: This article provides factual information and context on the GSK shares and does not constitute investment advice or a recommendation to buy or sell any security.
